Exscientia (EXAI) said Wednesday it expects to receive in Q4 a total of $15 million in milestone payments after advancing two drug programs in its collaboration with Sanofi (SNY).
Exscientia said both compounds met the requirements set by both companies to enable a transition to an optimization phase in the collaboration.
The drug development company said it remains eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million as well as tiered royalties as part of the Sanofi collaboration.